Publication
Article
Venous Thromboembolism After Total Hip Arthroplasty and Total Knee Arthroplasty: Current and Future Perspectives
This supplement to The American Journal of Managed Care reviews the clinical and economic burden of venous thromboembolism (VTE), the prevalence of VTE after total hip arthroplasty and total knee arthroplasty, and evidence-based clinical practice guidelines for thromboprophylaxis. Anticoagulants available today and new oral agents currently in development are discussed. The benefits of the new oral anticoagulants are outlined, in terms of their potential for cost reduction.
Faculty
Onur Baser, PhD
Assistant Professor of Surgery
University of Michigan
President, STATinMED Research
The University of Michigan and STATinMED Research
Ann Arbor, Michigan
William D. Fisher, MD
Associate Professor
Interim Chief of Orthopaedic Surgery
Associate Professor
Department of Surgery
McGill University Health Centre
Montreal, Quebec, Canada
Louis M. Kwong, MD, FACS
Professor of Orthopaedic Surgery
Department of Orthopaedic Surgery
Harbor-UCLA Medical Center
Torrance, California
Geno Merli, MD, FACP, FHM, FSVM
Professor of Medicine
Jefferson Medical College
Director, Jefferson Center for Vascular Disease
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Edith Nutescu, PharmD, FCCP
Clinical Professor
Antithrombosis Center/Center for Pharmacoeconomic Research
Department of Pharmacy Practice and Pharmacy Administration
College of Pharmacy
University of Illinois at Chicago
Chicago, Illinois
Acknowledgment
The authors would like to acknowledge Chris Thomas, who provided editorial support with funding from Ortho-McNeil Janssen Scientific Affairs, LLC.
Faculty Disclosures
These faculty members have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.
Onur Baser, PhD
, has nothing to disclose.
William D. Fisher, MD
Grants/honoraria:
Bayer
Portola
sanofi-aventis
Takeda
Lecturer:
Bayer
Boehringer Ingelheim
Johnson & Johnson
sanofi-aventis
Conference attendance:
Bayer
Johnson & Johnson
Louis M. Kwong, MD, FACS
Editorial board:
Journal of Surgical Orthopaedic Advances
Consultant/advisory board:
Zimmer
Honoraria:
GlaxoSmithKline
Grants:
Astellas
Bayer
GlaxoSmithKline
sanofi-aventis
Takeda
Geno Merli, MD, FACP, FHM, FSVM
Consultant/advisory board:
Bayer
Bristol-Myers Squibb
sanofi-aventis
Grants/Lecturer:
Bayer
Bristol-Myers Squibb
sanofi-aventis
Edith Nutescu, PharmD, FCCP
Grants/advisory board:
Ortho-McNeil Janssen Scientific Affairs, LLC
Venous Thromboembolism After Total Hip Arthroplasty and Total Knee Arthroplasty: Current and Future Perspectives
This supplement was made possible with the support of Ortho-McNeil Janssen Scientific Affairs, LLC and Johnson & Johnson Worldwide Market Access.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.